Gynecologic cancers:
Indications for HEXALEN:
Palliative treatment of persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
Adult Dosage:
260mg/m2 daily in four divided doses (after meals and at bedtime), for either 14 or 21 consecutive days in a 28-day cycle. Discontinue for >14 days if GI intolerance is unresponsive to treatment, WBC count <2000/mm3 or granulocyte count <1000/mm3, platelet count <75000/mm3, or progressive neurotoxicity occurs. Restart at 200mg/m2 daily. Discontinue indefinitely if neurologic symptoms fail to stabilize.
Children Dosage:
Not recommended.
HEXALEN Contraindications:
Severe myelosuppression or neurologic toxicity, except cisplatin-related neuropathy.
HEXALEN Warnings/Precautions:
Monitor for myelosuppression (do monthly CBCs) and neurotoxicity. Pregnancy (Cat.D). Nursing mothers: not recommended.
HEXALEN Classification:
S-triazine derivative.
HEXALEN Interactions:
Avoid pyridoxine. Severe orthostatic hypotension with MAOIs.
Adverse Reactions:
Nausea, vomiting, peripheral neuropathy, CNS symptoms (eg, mood disorders, ataxia, dizziness), myelosuppression, renal dysfunction, increased alkaline phosphatase.
How Supplied:
Caps—100
